Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-219CX in B Cell-Related Autoimmune Disease
NCT07586267Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QT-219CX in systemic lupus erythematosus (SLE), nephrotic syndrome, IgA nephropathy (IgAN) and 2 more, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 90 days and 1 more. Started May 2026; status: recruiting.
02
Drugs
QT-219CX
03
Conditions
systemic lupus erythematosus (SLE)nephrotic syndromeIgA nephropathy (IgAN)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07586267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586267.